Biomarin Pharmaceutical Inc (BMRN)
Debt-to-capital ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | 595,138 | 593,095 | 1,083,020 | 1,079,080 | 1,075,140 |
| Total stockholders’ equity | US$ in thousands | 5,657,990 | 4,951,550 | 4,603,160 | 4,265,670 | 4,100,930 |
| Debt-to-capital ratio | 0.10 | 0.11 | 0.19 | 0.20 | 0.21 |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $595,138K ÷ ($595,138K + $5,657,990K)
= 0.10
The debt-to-capital ratio of Biomarin Pharmaceutical Inc has exhibited a declining trend over the past five years. As of December 31, 2020, the ratio stood at 0.21, decreasing slightly to 0.20 by December 31, 2021, and further to 0.19 by December 31, 2022. The most significant drop occurred by December 31, 2023, when the ratio decreased to 0.11, indicating a substantial reduction in the company's reliance on debt financing relative to its total capital. By December 31, 2024, the ratio decreased marginally to 0.10, reflecting a continued trend of improved debt management and greater capital stability within Biomarin Pharmaceutical Inc. This declining trend suggests that the company has been effectively managing its debt levels and enhancing its overall financial health over the specified period.
Peer comparison
Dec 31, 2024